Market Cap 3.13B
Revenue (ttm) 398.99M
Net Income (ttm) -257.10M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -64.44%
Debt to Equity Ratio 0.22
Volume 1,004,900
Avg Vol 692,476
Day's Range N/A - N/A
Shares Out 111.76M
Stochastic %K 6%
Beta 1.08
Analysts Strong Sell
Price Target $56.00

Company Profile

Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for commu...

Industry: Biotechnology
Sector: Healthcare
Phone: 86 21 6163 2588
Address:
Building B, 899 Halei Road, Pudong, China
Pika_Capital
Pika_Capital Oct. 24 at 4:04 PM
$ZLAB around 25% down since I exited while bio sector is ripping NEVER marry stocks. Thesis changes, you don't like something, you fcking sell IMMEDIATELY. Even for loss. There are gazillion of other tickers. Plus I'm always open to reenter if I start liking things again
1 · Reply
SodApOp_PIMPski
SodApOp_PIMPski Oct. 24 at 3:37 PM
$ZLAB hold my nose and hope this is a double bottom buy
1 · Reply
SodApOp_PIMPski
SodApOp_PIMPski Oct. 24 at 3:33 PM
$ZLAB fire sale
0 · Reply
Quantumup
Quantumup Oct. 20 at 8:20 PM
Mizuho🏁 $RVMD Outperform/$90 $ZLAB AMGN BMY VSTM $IMRX Mizuho in its initiation report said: We see RVMD's portfolio of RAS(ON) inhibitors as positioned to play significant roles in PDAC, NSCLC and CRC. Specifically, we believe daraxonrasib in PDAC alone and additional near-term de-risking can drive meaningful upside. First, we expect future 1L PDAC updates and insights into PFS/OS to mature favorably and drive greater conviction around the Phase III RASolute 303 study. Second, scenario modeling of the Phase III RAsolute 302 trial in 2L PDAC points to a high probability of success, and we believe control arm overperformance, daraxonrasib underperformance and high drop out are all needed to put the study at risk. Altogether, the portfolio could generate $10B+ in risk-adjusted 2035 WW sales. We expect positive Phase III 2L PDAC data in 2026, and additional earlier-stage updates to drive outperformance over the next 12 months.
0 · Reply
Quantumup
Quantumup Oct. 17 at 3:09 PM
Raymond James⬆️ $RVMD's PT to $76 from $72/keeps at a Strong Buy after RevMed was included in the FDA's NPVR program. $ZLAB $AMGN $BMY VSTM $IMRX BofA⬆️to $80 from $78/reit'd Buy-Top Pick after RevMed was awarded one of the nine NPRVs for daraxonrasib in PDAC. Raymond James and BofA said in their notes to investors:
3 · Reply
lucgallo
lucgallo Oct. 15 at 11:44 AM
$ZLAB https://www.reuters.com/business/healthcare-pharmaceuticals/pfizer-ceo-says-us-pharma-industry-needs-collaborate-with-china-2025-10-15/
0 · Reply
SelfMafia
SelfMafia Oct. 14 at 11:44 PM
$ZLAB ME SCAM U LONG TIME
0 · Reply
Tdorsey1776
Tdorsey1776 Oct. 10 at 5:51 PM
$ZLAB B 3500, looking for it to work back above $32
0 · Reply
Tdorsey1776
Tdorsey1776 Oct. 10 at 4:04 PM
$ZLAB Domestic SINO sales only, they do not export to the US
0 · Reply
lucgallo
lucgallo Sep. 25 at 1:07 PM
$ZLAB https://ir.zailaboratory.com/news-releases/news-release-details/vertex-announces-key-advancements-across-kidney-portfolio
0 · Reply
Latest News on ZLAB
Zai Lab's Double Whammy: Earnings Miss, Phase 3 Setback

Sep 11, 2025, 8:02 AM EDT - 6 weeks ago

Zai Lab's Double Whammy: Earnings Miss, Phase 3 Setback


Zai Lab Establishes Oncology Scientific Advisory Board

Aug 13, 2025, 11:00 AM EDT - 2 months ago

Zai Lab Establishes Oncology Scientific Advisory Board


Zai Lab Limited (ZLAB) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 10:29 PM EDT - 2 months ago

Zai Lab Limited (ZLAB) Q2 2025 Earnings Call Transcript


Zai Lab Limited Is Well Positioned For Long-Term Growth

May 28, 2025, 2:48 AM EDT - 5 months ago

Zai Lab Limited Is Well Positioned For Long-Term Growth


Zai Lab Limited: Banking On Chinese Pharma Growth

May 22, 2025, 11:25 AM EDT - 5 months ago

Zai Lab Limited: Banking On Chinese Pharma Growth


Zai Lab Limited (ZLAB) Q1 2025 Earnings Call Transcript

May 11, 2025, 8:55 AM EDT - 5 months ago

Zai Lab Limited (ZLAB) Q1 2025 Earnings Call Transcript


Zai Lab Limited (ZLAB) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 10:46 PM EST - 8 months ago

Zai Lab Limited (ZLAB) Q4 2024 Earnings Call Transcript


Zai Lab: Rapidly Improving Outlook Bodes Well For The Future

Dec 26, 2024, 2:31 PM EST - 10 months ago

Zai Lab: Rapidly Improving Outlook Bodes Well For The Future


Zai Lab Limited (ZLAB) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 11:53 AM EST - 1 year ago

Zai Lab Limited (ZLAB) Q3 2024 Earnings Call Transcript


Pika_Capital
Pika_Capital Oct. 24 at 4:04 PM
$ZLAB around 25% down since I exited while bio sector is ripping NEVER marry stocks. Thesis changes, you don't like something, you fcking sell IMMEDIATELY. Even for loss. There are gazillion of other tickers. Plus I'm always open to reenter if I start liking things again
1 · Reply
SodApOp_PIMPski
SodApOp_PIMPski Oct. 24 at 3:37 PM
$ZLAB hold my nose and hope this is a double bottom buy
1 · Reply
SodApOp_PIMPski
SodApOp_PIMPski Oct. 24 at 3:33 PM
$ZLAB fire sale
0 · Reply
Quantumup
Quantumup Oct. 20 at 8:20 PM
Mizuho🏁 $RVMD Outperform/$90 $ZLAB AMGN BMY VSTM $IMRX Mizuho in its initiation report said: We see RVMD's portfolio of RAS(ON) inhibitors as positioned to play significant roles in PDAC, NSCLC and CRC. Specifically, we believe daraxonrasib in PDAC alone and additional near-term de-risking can drive meaningful upside. First, we expect future 1L PDAC updates and insights into PFS/OS to mature favorably and drive greater conviction around the Phase III RASolute 303 study. Second, scenario modeling of the Phase III RAsolute 302 trial in 2L PDAC points to a high probability of success, and we believe control arm overperformance, daraxonrasib underperformance and high drop out are all needed to put the study at risk. Altogether, the portfolio could generate $10B+ in risk-adjusted 2035 WW sales. We expect positive Phase III 2L PDAC data in 2026, and additional earlier-stage updates to drive outperformance over the next 12 months.
0 · Reply
Quantumup
Quantumup Oct. 17 at 3:09 PM
Raymond James⬆️ $RVMD's PT to $76 from $72/keeps at a Strong Buy after RevMed was included in the FDA's NPVR program. $ZLAB $AMGN $BMY VSTM $IMRX BofA⬆️to $80 from $78/reit'd Buy-Top Pick after RevMed was awarded one of the nine NPRVs for daraxonrasib in PDAC. Raymond James and BofA said in their notes to investors:
3 · Reply
lucgallo
lucgallo Oct. 15 at 11:44 AM
$ZLAB https://www.reuters.com/business/healthcare-pharmaceuticals/pfizer-ceo-says-us-pharma-industry-needs-collaborate-with-china-2025-10-15/
0 · Reply
SelfMafia
SelfMafia Oct. 14 at 11:44 PM
$ZLAB ME SCAM U LONG TIME
0 · Reply
Tdorsey1776
Tdorsey1776 Oct. 10 at 5:51 PM
$ZLAB B 3500, looking for it to work back above $32
0 · Reply
Tdorsey1776
Tdorsey1776 Oct. 10 at 4:04 PM
$ZLAB Domestic SINO sales only, they do not export to the US
0 · Reply
lucgallo
lucgallo Sep. 25 at 1:07 PM
$ZLAB https://ir.zailaboratory.com/news-releases/news-release-details/vertex-announces-key-advancements-across-kidney-portfolio
0 · Reply
Andy_InTheMoney
Andy_InTheMoney Sep. 18 at 8:14 PM
$ZLAB this Chinese name hasn’t moved yet, seems ready with earnings will be double digit growth this year
0 · Reply
Quantumup
Quantumup Sep. 18 at 12:28 PM
Barclays🏁 $ONC Overweight-$385 and said, BeOne (ONC) is a commercial oncology company developing therapies across hematologic and solid tumors. $ONC's broad oncology pipeline positions it for durable growth. Barclay additionally said: We initiate coverage of BeOne (ONC) with an Overweight rating and $385 PT, ahead of two value-inflecting pivotal data readouts; 1) Data for BTK inhibitor in first line mantle cell lymphoma in 2H25; and 2) Data in first line gastroesophageal cancer for PD1 inhibitor + anti-HER2 combination in 4Q25. $ZLAB $PFE $LLY $ABBV
0 · Reply
Mik21212
Mik21212 Sep. 12 at 2:26 PM
$ZLAB up to 34$
0 · Reply
Quantumup
Quantumup Sep. 12 at 9:50 AM
Mizuho reiterated $IDYA Outperform-$44 & said we attended $IDYA's R&D Day earlier this week, with the company featuring presentations on its five highest-priority R&D assets: (1) darovasertib for uveal melanoma/UM; (2) IDE397, a novel MAT2A candidate for MTAP-deleted solid tumors; (3) IDE849, an emerging DLL3-TOP1 ADC candidate; (4) IDE161, a novel PARG inhibitor; and (5) IDE892, a potentially best-in-class PRMT5 inhibitor. Overall, we walked away positively, as we continue to be impressed by $IDYA's ability to execute. On lead asset daro, following the updates we heard (including supportive comments by an uveal melanoma expert), we increase our probability of success/POS assumption to 70% (vs. 60% prior) in the neoadjuvant UM setting, and on other model updates, our PT moves to $44. With the stock down 8% post-the R&D Day event, additional pipeline newsflow expected in the near-term, and model upside from pipeline assets not currently modeled, we stay OP-rated on $IDYA. $AZN $RHHBY $BMY $ZLAB
0 · Reply
Polip
Polip Sep. 12 at 6:26 AM
$ZLAB China stay away from
0 · Reply
Mik21212
Mik21212 Sep. 11 at 7:48 PM
$ZLAB 😎😎😎
0 · Reply
RayRex123
RayRex123 Sep. 11 at 4:26 PM
$ZLAB you mean above $40
1 · Reply
Tdorsey1776
Tdorsey1776 Sep. 11 at 1:34 PM
$ZLAB Needs to get back above $32
0 · Reply
doubleyou2
doubleyou2 Sep. 10 at 9:14 PM
$ZLAB I wish i had more money available at the miment to add here.
0 · Reply
doubleyou2
doubleyou2 Sep. 10 at 8:25 PM
$ZLAB You have cheap. You have very cheap. And you have ZaiLab. Quality company, almost for free. You almost don't find a company with such product pipelines. It is just amazing. If this was a 100% US company, the stockprice would be between $150 and $200. Trump or no Trump...one day this company will be a Big Pharma player.
0 · Reply
Mik21212
Mik21212 Sep. 10 at 5:49 PM
$ZLAB fear creates opportunities😎
0 · Reply
Tdorsey1776
Tdorsey1776 Sep. 10 at 2:51 PM
$ZLAB No impact on ZLAB business other than perception.
1 · Reply